Graypoint LLC cut its holdings in Novartis AG (NYSE:NVS – Free Report) by 33.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,759 shares of the company’s stock after selling 1,909 shares during the quarter. Graypoint LLC’s holdings in Novartis were worth $400,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in NVS. Frazier Financial Advisors LLC bought a new stake in Novartis during the fourth quarter worth $26,000. Private Ocean LLC purchased a new stake in Novartis in the 1st quarter worth about $25,000. Richardson Financial Services Inc. purchased a new stake in Novartis in the 4th quarter worth about $26,000. New Millennium Group LLC purchased a new stake in Novartis in the 2nd quarter worth about $28,000. Finally, Clearstead Trust LLC boosted its stake in Novartis by 73.5% in the 1st quarter. Clearstead Trust LLC now owns 269 shares of the company’s stock worth $26,000 after purchasing an additional 114 shares during the period. 13.12% of the stock is owned by institutional investors and hedge funds.
Novartis Price Performance
NYSE:NVS opened at $120.89 on Monday. The firm has a market capitalization of $247.10 billion, a price-to-earnings ratio of 16.31, a PEG ratio of 1.77 and a beta of 0.57. Novartis AG has a 1 year low of $92.19 and a 1 year high of $120.92. The business has a 50 day simple moving average of $111.51 and a 200-day simple moving average of $103.93. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.93 and a quick ratio of 0.72.
Analyst Upgrades and Downgrades
Several research analysts have commented on the company. Jefferies Financial Group raised their target price on Novartis from $121.00 to $122.50 and gave the stock a “buy” rating in a research note on Tuesday, July 2nd. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Novartis in a research note on Friday, July 19th. Barclays raised Novartis to a “strong sell” rating in a research note on Monday, June 24th. Finally, The Goldman Sachs Group started coverage on Novartis in a research note on Thursday, May 30th. They issued a “buy” rating and a $120.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Novartis presently has a consensus rating of “Hold” and a consensus price target of $118.13.
View Our Latest Stock Report on NVS
About Novartis
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
See Also
- Five stocks we like better than Novartis
- Stock Average Calculator
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
- Trading Stocks: RSI and Why it’s Useful
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Why Dell Can Continue Winning in AI and Beyond
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS – Free Report).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.